{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T23:01:43Z","timestamp":1789599703535,"version":"build-2803163510"},"reference-count":50,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,5,1]],"date-time":"2014-05-01T00:00:00Z","timestamp":1398902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,5,1]],"date-time":"2014-05-01T00:00:00Z","timestamp":1398902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.1124\/jpet.114.213256","type":"journal-article","created":{"date-parts":[[2014,2,26]],"date-time":"2014-02-26T05:56:03Z","timestamp":1393394163000},"page":"258-267","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":61,"title":["Tolvaptan Delays the Onset of End-Stage Renal Disease in a Polycystic Kidney Disease Model by Suppressing Increases in Kidney Volume and Renal Injury"],"prefix":"10.1016","volume":"349","author":[{"given":"Miki","family":"Aihara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Fujiki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Mizuguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuji","family":"Hattori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Ohmoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Nagano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshitaka","family":"Yamamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.114.213256_bib1","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1093\/ndt\/18.3.497","article-title":"Vasopressin increases urinary albumin excretion in rats and humans: involvement of V2 receptors and the renin-angiotensin system","volume":"18","author":"Bardoux","year":"2003","journal-title":"Nephrol Dial Transplant"},{"key":"10.1124\/jpet.114.213256_bib2","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1093\/ndt\/gfg277","article-title":"Diabetes-induced albuminuria: role of antidiuretic hormone as revealed by chronic V2 receptor antagonism in rats","volume":"18","author":"Bardoux","year":"2003","journal-title":"Nephrol Dial Transplant"},{"key":"10.1124\/jpet.114.213256_bib3","doi-asserted-by":"crossref","first-page":"c25","DOI":"10.1159\/000334166","article-title":"Mechanism-based therapeutics for autosomal dominant polycystic kidney disease: recent progress and future prospects","volume":"120","author":"Chang","year":"2012","journal-title":"Nephron Clin Pract"},{"key":"10.1124\/jpet.114.213256_bib4","doi-asserted-by":"crossref","first-page":"479","DOI":"10.2215\/CJN.09500911","article-title":"Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease","volume":"7","author":"Chapman","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1124\/jpet.114.213256_bib5","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1681\/ASN.2012070650","article-title":"Type of PKD1 mutation influences renal outcome in ADPKD","volume":"24","author":"Cornec-Le Gall","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"10.1124\/jpet.114.213256_bib6","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.1093\/ndt\/gfq195","article-title":"Distinct patterns of kidney and liver cyst growth in pkd2(WS25\/-) mice","volume":"25","author":"Doctor","year":"2010","journal-title":"Nephrol Dial Transplant"},{"issue":"Suppl 1","key":"10.1124\/jpet.114.213256_bib7","doi-asserted-by":"crossref","first-page":"S83","DOI":"10.1007\/s10557-011-6357-x","article-title":"Nonclinical pharmacokinetics of a new nonpeptide V2 receptor antagonist, tolvaptan","volume":"25","author":"Furukawa","year":"2011","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1124\/jpet.114.213256_bib8","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1038\/nm935","article-title":"Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist","volume":"9","author":"Gattone","year":"2003","journal-title":"Nat Med"},{"key":"10.1124\/jpet.114.213256_bib9","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1056\/NEJMcp0804458","article-title":"Clinical practice. Autosomal dominant polycystic kidney disease","volume":"359","author":"Grantham","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1124\/jpet.114.213256_bib10","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1056\/NEJMoa054341","article-title":"Volume progression in polycystic kidney disease","volume":"354","author":"Grantham","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1124\/jpet.114.213256_bib11","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0140-6736(98)03495-3","article-title":"Comparison of phenotypes of polycystic kidney disease type 1 and 2","volume":"353","author":"Hateboer","year":"1999","journal-title":"Lancet"},{"key":"10.1124\/jpet.114.213256_bib12","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.2215\/CJN.03530411","article-title":"Tolvaptan in autosomal dominant polycystic kidney disease: three years\u2019 experience","volume":"6","author":"Higashihara","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1124\/jpet.114.213256_bib13","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/S0022-3565(24)35289-9","article-title":"Effects of the V(2)-receptor antagonist OPC-41061 and the loop diuretic furosemide alone and in combination in rats","volume":"292","author":"Hirano","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.114.213256_bib14","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.ygeno.2004.03.009","article-title":"New insights into ADPKD molecular pathways using combination of SAGE and microarray technologies","volume":"84","author":"Husson","year":"2004","journal-title":"Genomics"},{"key":"10.1124\/jpet.114.213256_bib15","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1016\/S0968-0896(99)00101-7","article-title":"7-Chloro-5-hydroxy-1-[2-methyl-4-(2-methylbenzoyl-amino)benzoyl]-2,3,4,5-tetrahydro-1H-1-benzazepine (OPC-41061): a potent, orally active nonpeptide arginine vasopressin V2 receptor antagonist","volume":"7","author":"Kondo","year":"1999","journal-title":"Bioorg Med Chem"},{"key":"10.1124\/jpet.114.213256_bib16","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1681\/ASN.2011090907","article-title":"Biomarkers predict progression of acute kidney injury after cardiac surgery","volume":"23","author":"Koyner","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"10.1124\/jpet.114.213256_bib17","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/ki.2008.499","article-title":"Urinary neutrophil gelatinase-associated lipocalin levels reflect damage to glomeruli, proximal tubules, and distal nephrons","volume":"75","author":"Kuwabara","year":"2009","journal-title":"Kidney Int"},{"key":"10.1124\/jpet.114.213256_bib18","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/5944","article-title":"Late onset of renal and hepatic cysts in Pkd1-targeted heterozygotes","volume":"21","author":"Lu","year":"1999","journal-title":"Nat Genet"},{"key":"10.1124\/jpet.114.213256_bib19","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1002\/hep.26140","article-title":"Pasireotide is more effective than octreotide in reducing hepatorenal cystogenesis in rodents with polycystic kidney and liver diseases","volume":"58","author":"Masyuk","year":"2013","journal-title":"Hepatology"},{"issue":"Suppl 1","key":"10.1124\/jpet.114.213256_bib20","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1007\/s10557-011-6304-x","article-title":"Efficacy and safety of tolvaptan in heart failure patients with volume overload despite the standard treatment with conventional diuretics: a phase III, randomized, double-blind, placebo-controlled study (QUEST study)","volume":"25","author":"Matsuzaki","year":"2011","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1124\/jpet.114.213256_bib21","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1136\/bmj.1.6070.1196","article-title":"Clinical aspects of polycystic disease of the kidneys","volume":"1","author":"Mitcheson","year":"1977","journal-title":"BMJ"},{"issue":"5266, S266","key":"10.1124\/jpet.114.213256_bib22","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1126\/science.272.5266.1339","article-title":"PKD2, a gene for polycystic kidney disease that encodes an integral membrane protein","volume":"272","author":"Mochizuki","year":"1996","journal-title":"Science"},{"key":"10.1124\/jpet.114.213256_bib23","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/sj.ki.5002165","article-title":"Neutrophil gelatinase-associated lipocalin as the real-time indicator of active kidney damage","volume":"71","author":"Mori","year":"2007","journal-title":"Kidney Int"},{"key":"10.1124\/jpet.114.213256_bib24","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/sj.ki.5002627","article-title":"Overexpression of innate immune response genes in a model of recessive polycystic kidney disease","volume":"73","author":"Mrug","year":"2008","journal-title":"Kidney Int"},{"key":"10.1124\/jpet.114.213256_bib25","first-page":"45","article-title":"Strain difference in expression of the adult-type polycystic kidney disease gene, pcy, in the mouse","volume":"40","author":"Nagao","year":"1991","journal-title":"Jikken Dobutsu"},{"key":"10.1124\/jpet.114.213256_bib26","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1538\/expanim.61.477","article-title":"Animal models for human polycystic kidney disease","volume":"61","author":"Nagao","year":"2012","journal-title":"Exp Anim"},{"key":"10.1124\/jpet.114.213256_bib27","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/ng1216","article-title":"Mutations in a novel gene, NPHP3, cause adolescent nephronophthisis, tapeto-retinal degeneration and hepatic fibrosis","volume":"34","author":"Olbrich","year":"2003","journal-title":"Nat Genet"},{"key":"10.1124\/jpet.114.213256_bib28","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1038\/ki.2011.465","article-title":"Evaluation of urine biomarkers of kidney injury in polycystic kidney disease","volume":"81","author":"Parikh","year":"2012","journal-title":"Kidney Int"},{"key":"10.1124\/jpet.114.213256_bib29","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/1471-2369-13-93","article-title":"Urinary N-acetyl-\u03b2-D glucosaminidase as a surrogate marker for renal function in autosomal dominant polycystic kidney disease: 1 year prospective cohort study","volume":"13","author":"Park","year":"2012","journal-title":"BMC Nephrol"},{"key":"10.1124\/jpet.114.213256_bib30","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s10334-008-0158-7","article-title":"Monitoring kidney and renal cyst volumes applying MR approaches on a rapamycin treated mouse model of ADPKD","volume":"22","author":"Reichardt","year":"2009","journal-title":"MAGMA"},{"key":"10.1124\/jpet.114.213256_bib31","doi-asserted-by":"crossref","first-page":"F1005","DOI":"10.1152\/ajprenal.00243.2011","article-title":"Tolvaptan inhibits ERK-dependent cell proliferation, Cl\u207b secretion, and in vitro cyst growth of human ADPKD cells stimulated by vasopressin","volume":"301","author":"Reif","year":"2011","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1124\/jpet.114.213256_bib32","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1038\/sj.ki.5000309","article-title":"Transcriptome analysis of a rat PKD model: importance of genes involved in extracellular matrix metabolism","volume":"69","author":"Riera","year":"2006","journal-title":"Kidney Int"},{"key":"10.1124\/jpet.114.213256_bib33","doi-asserted-by":"crossref","first-page":"560","DOI":"10.2215\/CJN.02410508","article-title":"Quality of life in autosomal dominant polycystic kidney disease patients not yet on dialysis","volume":"4","author":"Rizk","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1124\/jpet.114.213256_bib34","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/hepr.12098","article-title":"Tolvaptan for improvement of hepatic edema: a phase 3, multicenter, randomized, double-blind, placebo-controlled trial","volume":"44","author":"Sakaida","year":"2014","journal-title":"Hepatol Res"},{"key":"10.1124\/jpet.114.213256_bib35","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1056\/NEJMoa065181","article-title":"Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia","volume":"355","author":"Schrier","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1124\/jpet.114.213256_bib36","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1177\/0091270007307877","article-title":"Pharmacokinetics, pharmacodynamics, and safety of tolvaptan, a nonpeptide AVP antagonist, during ascending single-dose studies in healthy subjects","volume":"47","author":"Shoaf","year":"2007","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/jpet.114.213256_bib37","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1681\/ASN.2006020136","article-title":"Development of polycystic kidney disease in juvenile cystic kidney mice: insights into pathogenesis, ciliary abnormalities, and common features with human disease","volume":"17","author":"Smith","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"10.1124\/jpet.114.213256_bib38","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1681\/ASN.V17980","article-title":"A hereditary model of slowly progressive polycystic kidney disease in the mouse","volume":"1","author":"Takahashi","year":"1991","journal-title":"J Am Soc Nephrol"},{"key":"10.1124\/jpet.114.213256_bib39","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","article-title":"Tolvaptan in patients with autosomal dominant polycystic kidney disease","volume":"367","author":"Torres","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1124\/jpet.114.213256_bib40","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1365-2796.2006.01743.x","article-title":"Polycystic kidney disease: genes, proteins, animal models, disease mechanisms and therapeutic opportunities","volume":"261","author":"Torres","year":"2007","journal-title":"J Intern Med"},{"key":"10.1124\/jpet.114.213256_bib41","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/S0140-6736(07)60601-1","article-title":"Autosomal dominant polycystic kidney disease","volume":"369","author":"Torres","year":"2007","journal-title":"Lancet"},{"key":"10.1124\/jpet.114.213256_bib42","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/nm1004","article-title":"Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease","volume":"10","author":"Torres","year":"2004","journal-title":"Nat Med"},{"key":"10.1124\/jpet.114.213256_bib43","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1016\/j.bbadis.2010.11.005","article-title":"Cyclic AMP-mediated cyst expansion","volume":"1812","author":"Wallace","year":"2011","journal-title":"Biochim Biophys Acta"},{"key":"10.1124\/jpet.114.213256_bib44","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1681\/ASN.2004121090","article-title":"Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat","volume":"16","author":"Wang","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1124\/jpet.114.213256_bib45","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1681\/ASN.2007060688","article-title":"Vasopressin directly regulates cyst growth in polycystic kidney disease","volume":"19","author":"Wang","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"10.1124\/jpet.114.213256_bib46","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/S0272-6386(97)90496-0","article-title":"Renal accumulation and excretion of cyclic adenosine monophosphate in a murine model of slowly progressive polycystic kidney disease","volume":"30","author":"Yamaguchi","year":"1997","journal-title":"Am J Kidney Dis"},{"key":"10.1124\/jpet.114.213256_bib47","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1046\/j.1523-1755.2003.00023.x","article-title":"Cyclic AMP activates B-Raf and ERK in cyst epithelial cells from autosomal-dominant polycystic kidneys","volume":"63","author":"Yamaguchi","year":"2003","journal-title":"Kidney Int"},{"key":"10.1124\/jpet.114.213256_bib48","doi-asserted-by":"crossref","first-page":"40419","DOI":"10.1074\/jbc.M405079200","article-title":"Calcium restriction allows cAMP activation of the B-Raf\/ERK pathway, switching cells to a cAMP-dependent growth-stimulated phenotype","volume":"279","author":"Yamaguchi","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1124\/jpet.114.213256_bib49","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/S0022-3565(24)37873-5","article-title":"OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats","volume":"287","author":"Yamamura","year":"1998","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.114.213256_bib50","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1111\/j.1476-5381.1992.tb09058.x","article-title":"Characterization of a novel aquaretic agent, OPC-31260, as an orally effective, nonpeptide vasopressin V2 receptor antagonist","volume":"105","author":"Yamamura","year":"1992","journal-title":"Br J Pharmacol"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524272761?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524272761?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.114.213256","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T20:12:24Z","timestamp":1739995944000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524272761"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5]]},"references-count":50,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,5]]}},"alternative-id":["S0022356524272761"],"URL":"https:\/\/doi.org\/10.1124\/jpet.114.213256","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2014,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tolvaptan Delays the Onset of End-Stage Renal Disease in a Polycystic Kidney Disease Model by Suppressing Increases in Kidney Volume and Renal Injury","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.114.213256","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2014 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}